Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium

David C. Muller; Tricia L. Larose; Allison Hodge; Florence Guida; Arnulf Langhammer; Kjell Grankvist; Klaus Meyer; Qiuyin Cai; Alan A. Arslan; Anne Zeleniuch-Jacquotte; Demetrius Albanes; Graham G. Giles; Howard D. Sesso; I. Min Lee; J. Michael Gaziano; Jian Min Yuan; Judith Hoffman Bolton; Julie E. Buring; Kala Visvanathan; Loic Le Marchand; Mark P. Purdue; Neil E. Caporaso; Øivind Midttun; Per M. Ueland; Ross L. Prentice; Stephanie J. Weinstein; Victoria L. Stevens; Wei Zheng; William J. Blot; Xiao Ou Shu; Xuehong Zhang; Yong Bing Xiang; Woon Puay Koh; Kristian Hveem; Cynthia A. Thomson; Mary Pettinger; Gunnar Engström; Hans Brunnström; Roger L. Milne; Meir J. Stampfer; Jiali Han; Mikael Johansson; Paul Brennan; Gianluca Severi; Mattias Johansson

doi:10.1136/bmj.k4981

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium

David C. Muller, Tricia L. Larose, Allison Hodge, Florence Guida, Arnulf Langhammer, Kjell Grankvist, Klaus Meyer, Qiuyin Cai, Alan A. Arslan, Anne Zeleniuch-Jacquotte, Demetrius Albanes, Graham G. Giles, Howard D. Sesso, I. Min Lee, J. Michael Gaziano, Jian Min Yuan, Judith Hoffman Bolton, Julie E. Buring, Kala Visvanathan, Loic Le MarchandMark P. Purdue, Neil E. Caporaso, Øivind Midttun, Per M. Ueland, Ross L. Prentice, Stephanie J. Weinstein, Victoria L. Stevens, Wei Zheng, William J. Blot, Xiao Ou Shu, Xuehong Zhang, Yong Bing Xiang, Woon Puay Koh, Kristian Hveem, Cynthia A. Thomson, Mary Pettinger, Gunnar Engström, Hans Brunnström, Roger L. Milne, Meir J. Stampfer, Jiali Han, Mikael Johansson, Paul Brennan, Gianluca Severi, Mattias Johansson

Health Promotion Sciences

Research output: Contribution to journal › Article

4 Scopus citations

Abstract

Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.

Original language	English (US)
Journal	BMJ (Online)
Volume	364
DOIs	https://doi.org/10.1136/bmj.k4981
State	Published - 2019

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1136/bmj.k4981

Fingerprint Dive into the research topics of 'Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium'. Together they form a unique fingerprint.

Cite this

Muller, D. C., Larose, T. L., Hodge, A., Guida, F., Langhammer, A., Grankvist, K., Meyer, K., Cai, Q., Arslan, A. A., Zeleniuch-Jacquotte, A., Albanes, D., Giles, G. G., Sesso, H. D., Lee, I. M., Gaziano, J. M., Yuan, J. M., Bolton, J. H., Buring, J. E., Visvanathan, K., ... Johansson, M. (2019). Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium. BMJ (Online), 364. https://doi.org/10.1136/bmj.k4981

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer : Nested case-control study within Lung Cancer Cohort Consortium. / Muller, David C.; Larose, Tricia L.; Hodge, Allison; Guida, Florence; Langhammer, Arnulf; Grankvist, Kjell; Meyer, Klaus; Cai, Qiuyin; Arslan, Alan A.; Zeleniuch-Jacquotte, Anne; Albanes, Demetrius; Giles, Graham G.; Sesso, Howard D.; Lee, I. Min; Gaziano, J. Michael; Yuan, Jian Min; Bolton, Judith Hoffman; Buring, Julie E.; Visvanathan, Kala; Le Marchand, Loic; Purdue, Mark P.; Caporaso, Neil E.; Midttun, Øivind; Ueland, Per M.; Prentice, Ross L.; Weinstein, Stephanie J.; Stevens, Victoria L.; Zheng, Wei; Blot, William J.; Shu, Xiao Ou; Zhang, Xuehong; Xiang, Yong Bing; Koh, Woon Puay; Hveem, Kristian; Thomson, Cynthia A.; Pettinger, Mary; Engström, Gunnar; Brunnström, Hans; Milne, Roger L.; Stampfer, Meir J.; Han, Jiali; Johansson, Mikael; Brennan, Paul; Severi, Gianluca; Johansson, Mattias.

In: BMJ (Online), Vol. 364, 2019.

Research output: Contribution to journal › Article

Muller, DC, Larose, TL, Hodge, A, Guida, F, Langhammer, A, Grankvist, K, Meyer, K, Cai, Q, Arslan, AA, Zeleniuch-Jacquotte, A, Albanes, D, Giles, GG, Sesso, HD, Lee, IM, Gaziano, JM, Yuan, JM, Bolton, JH, Buring, JE, Visvanathan, K, Le Marchand, L, Purdue, MP, Caporaso, NE, Midttun, Ø, Ueland, PM, Prentice, RL, Weinstein, SJ, Stevens, VL, Zheng, W, Blot, WJ, Shu, XO, Zhang, X, Xiang, YB, Koh, WP, Hveem, K, Thomson, CA, Pettinger, M, Engström, G, Brunnström, H, Milne, RL, Stampfer, MJ, Han, J, Johansson, M, Brennan, P, Severi, G & Johansson, M 2019, 'Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium', BMJ (Online), vol. 364. https://doi.org/10.1136/bmj.k4981

Muller, David C. ; Larose, Tricia L. ; Hodge, Allison ; Guida, Florence ; Langhammer, Arnulf ; Grankvist, Kjell ; Meyer, Klaus ; Cai, Qiuyin ; Arslan, Alan A. ; Zeleniuch-Jacquotte, Anne ; Albanes, Demetrius ; Giles, Graham G. ; Sesso, Howard D. ; Lee, I. Min ; Gaziano, J. Michael ; Yuan, Jian Min ; Bolton, Judith Hoffman ; Buring, Julie E. ; Visvanathan, Kala ; Le Marchand, Loic ; Purdue, Mark P. ; Caporaso, Neil E. ; Midttun, Øivind ; Ueland, Per M. ; Prentice, Ross L. ; Weinstein, Stephanie J. ; Stevens, Victoria L. ; Zheng, Wei ; Blot, William J. ; Shu, Xiao Ou ; Zhang, Xuehong ; Xiang, Yong Bing ; Koh, Woon Puay ; Hveem, Kristian ; Thomson, Cynthia A. ; Pettinger, Mary ; Engström, Gunnar ; Brunnström, Hans ; Milne, Roger L. ; Stampfer, Meir J. ; Han, Jiali ; Johansson, Mikael ; Brennan, Paul ; Severi, Gianluca ; Johansson, Mattias. / Circulating high sensitivity C reactive protein concentrations and risk of lung cancer : Nested case-control study within Lung Cancer Cohort Consortium. In: BMJ (Online). 2019 ; Vol. 364.

@article{2e94a04f9bce4f31b2a70b0e4d5f1fa8,

title = "Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium",

abstract = "Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.",

author = "Muller, {David C.} and Larose, {Tricia L.} and Allison Hodge and Florence Guida and Arnulf Langhammer and Kjell Grankvist and Klaus Meyer and Qiuyin Cai and Arslan, {Alan A.} and Anne Zeleniuch-Jacquotte and Demetrius Albanes and Giles, {Graham G.} and Sesso, {Howard D.} and Lee, {I. Min} and Gaziano, {J. Michael} and Yuan, {Jian Min} and Bolton, {Judith Hoffman} and Buring, {Julie E.} and Kala Visvanathan and {Le Marchand}, Loic and Purdue, {Mark P.} and Caporaso, {Neil E.} and {\O}ivind Midttun and Ueland, {Per M.} and Prentice, {Ross L.} and Weinstein, {Stephanie J.} and Stevens, {Victoria L.} and Wei Zheng and Blot, {William J.} and Shu, {Xiao Ou} and Xuehong Zhang and Xiang, {Yong Bing} and Koh, {Woon Puay} and Kristian Hveem and Thomson, {Cynthia A.} and Mary Pettinger and Gunnar Engstr{\"o}m and Hans Brunnstr{\"o}m and Milne, {Roger L.} and Stampfer, {Meir J.} and Jiali Han and Mikael Johansson and Paul Brennan and Gianluca Severi and Mattias Johansson",

year = "2019",

doi = "10.1136/bmj.k4981",

language = "English (US)",

volume = "364",

journal = "The BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Circulating high sensitivity C reactive protein concentrations and risk of lung cancer

T2 - Nested case-control study within Lung Cancer Cohort Consortium

AU - Muller, David C.

AU - Larose, Tricia L.

AU - Hodge, Allison

AU - Guida, Florence

AU - Langhammer, Arnulf

AU - Grankvist, Kjell

AU - Meyer, Klaus

AU - Cai, Qiuyin

AU - Arslan, Alan A.

AU - Zeleniuch-Jacquotte, Anne

AU - Albanes, Demetrius

AU - Giles, Graham G.

AU - Sesso, Howard D.

AU - Lee, I. Min

AU - Gaziano, J. Michael

AU - Yuan, Jian Min

AU - Bolton, Judith Hoffman

AU - Buring, Julie E.

AU - Visvanathan, Kala

AU - Le Marchand, Loic

AU - Purdue, Mark P.

AU - Caporaso, Neil E.

AU - Midttun, Øivind

AU - Ueland, Per M.

AU - Prentice, Ross L.

AU - Weinstein, Stephanie J.

AU - Stevens, Victoria L.

AU - Zheng, Wei

AU - Blot, William J.

AU - Shu, Xiao Ou

AU - Zhang, Xuehong

AU - Xiang, Yong Bing

AU - Koh, Woon Puay

AU - Hveem, Kristian

AU - Thomson, Cynthia A.

AU - Pettinger, Mary

AU - Engström, Gunnar

AU - Brunnström, Hans

AU - Milne, Roger L.

AU - Stampfer, Meir J.

AU - Han, Jiali

AU - Johansson, Mikael

AU - Brennan, Paul

AU - Severi, Gianluca

AU - Johansson, Mattias

PY - 2019

Y1 - 2019

N2 - Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.

AB - Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. cOnclusiOns Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.

UR - http://www.scopus.com/inward/record.url?scp=85059500268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059500268&partnerID=8YFLogxK

U2 - 10.1136/bmj.k4981

DO - 10.1136/bmj.k4981

M3 - Article

C2 - 30606716

AN - SCOPUS:85059500268

VL - 364

JO - The BMJ

JF - The BMJ

SN - 0959-8146

ER -